ClinicalTrials.gg
Enrolling by invitationNCT06083597PROM for CPPUpdated Dec 18, 2025

Development of a Patient-reported Outcome Measure for Women With Chronic Pelvic Pain

An observational study in Chronic Pelvic Pain Syndrome and Pelvic Congestive Syndrome, sponsored by Weill Medical College of Cornell University. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Weill Medical College of Cornell University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
55
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.

Planned enrollment
20th of 28
55 · median 104
Started
2023
with 6 others
Observational
28 of 152
9 open now
Primary completion
2026-12
later than 8 of 39 live
Registered
116th of 152
by date

Among the 152 studies in Pelvic Pain with a site in United States, this one is the 20th largest by planned enrollment of the 28 observational ones that give a count, is one of 7 that started in 2023, is one of 28 observational ones, reaches primary completion later than 8 of the 39 other live ones, and was the 116th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Pelvic Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to develop a patient questionnaire that can be utilized to assess the benefit of treatments of chronic pelvic pain in research studies.

The information collected from a series of patient interviews will lead to the development of a questionnaire that accounts for the full impact of chronic pelvic pain from an affected woman's perspective.

Read the detailed description

The purpose of this study is to develop a patient-reported outcome (PRO) instrument that can be utilized as an efficacy endpoint to assess medical and surgical treatments of chronic pelvic pain (CPP) in comparative outcomes research.

This instrument will be developed consistent with Food and Drug Administration (FDA) guidance to be appropriate as an efficacy measurement in a clinical trial. The development of such a PRO measure is iterative, and this research protocol includes the qualitative research to develop a draft measure and document content validity. Content validity is first assessed through concept elicitation interviews, followed by cognitive interviews.

Patients who are eligible and consent to participate will:

  1. complete a series of standardized health questionnaires
  2. participate in an interview with a scientist who is an expert at developing this kind of PRO instrument who will ask patients about the impacts of their COO on their overall health and well being.

The information collected from a series of these interviews will lead to the development of a draft questionnaire which will then be reviewed with additional women with similar causes of CPP as well as with women with other causes of CPP to determine its usability and accuracy at assessing the impacts of CPP on their health and well being.

A final version of the PROM instrument will then be shared with women with CPP before and after any treatment to determine its ability to identify changes in their health and wellbeing.

03

Conditions studied

  • Chronic Pelvic Pain Syndrome
  • Pelvic Congestive Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women with chronic pelvic pain (CPP) meeting the American College of Obstetricians and Gynecologists criteria.

Eligibility criteria

I. First phase of study evaluation women with presumed venous origin chronic pelvic pain

Inclusion Criteria :

  1. Non-menopausal women ≥18 years old.

    a. Women who are not menstruating because of ovarian suppression therapy for CPP are eligible.

  2. CPP meeting the American College of Obstetricians and Gynecologists criteria.
  3. Patient pain is primarily of pelvic and/or pelvic floor origin. Patient may experience other pain symptoms, including bowel, bladder, musculoskeletal, skin allodynia and hyperalgesia, or lower extremity venous or vulvar pain.
  4. Imaging demonstrating multiple tortuous pelvic varicose veins > 5 mm in diameter in the ovarian, utero vaginal, and/or uterine arcuate venous plexus.

    a. Imaging must be documented from trans vaginal ultrasound, trans abdominal ultrasound, magnetic resonance imaging, computed tomography, catheter venogram, or trans fundal pelvic venogram. If laparoscopic images are available to confirm veins this size, this would be acceptable as well.

  5. Venous contribution to CPP, as determined by clinical impression from a CPP specialist. Clinical impression will be based on the presence of the following symptoms and physical findings:

    a. Symptoms: i. CPP increased with standing, walking, or lifting ii. CPP increased at the end of the day iii. CPP improved by laying down iv. Sexually provoked prolonged post-coital ache b. Physical findings: i. Adnexal tenderness on gentle bimanual exam ii. Tenderness at the ovarian point trans-abdominally iii. Tenderness of the uterus

  6. Participant can read, communicate clearly, and understand English or Spanish.
  7. Participant is willing and able to participate in an interview and complete questionnaires.
  8. Participant is willing and able to provide .

Exclusion Criteria:

  1. Pain symptoms should primarily be of pelvic and/or pelvic floor origin (inclusion criteria #3 above). Pain should not be exclusively low back, hips, symphysis, allodynia or hyperalgesia of the skin, or from varicose veins of the vulvar and/or lower extremities.
  2. Pain thought primarily to be due to endometriosis, pelvic floor myalgia, a musculoskeletal etiology, irritable bowel disease, or painful bladder syndrome/interstitial cystitis.
  3. Obvious endometriosis based on physical exam or laparoscopy findings.
  4. Patients previously treated with a technically successful surgery or vascular procedure for a venous disorder of the pelvis or renal vein.
  5. Participant has any medical condition (e.g., severe co morbid condition, severe mental illness, severe visual or auditory impairment, or cognitive impairment) that, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures

II. Second phase of study evaluation women with non-venous origin chronic pelvic pain

Inclusion Criteria :

  1. Non-menopausal women ≥18 years old.

    a. Women who are not menstruating because of ovarian suppression therapy for CPP are eligible.

  2. CPP meeting the American College of Obstetricians and Gynecologists criteria.
  3. Patient pain is primarily of pelvic and/or pelvic floor origin. Patient may experience other pain symptoms, including bowel, bladder, musculoskeletal, skin allodynia and hyperalgesia, or lower extremity venous or vulvar pain.
  4. Imaging demonstrating multiple tortuous pelvic varicose veins > 5 mm in diameter in the ovarian, utero vaginal, and/or uterine arcuate venous plexus.

    a. Imaging must be documented from trans vaginal ultrasound, trans abdominal ultrasound, magnetic resonance imaging, computed tomography, catheter venogram, or trans fundal pelvic venogram. If laparoscopic images are available to confirm veins this size, this would be acceptable as well.

  5. Venous contribution to CPP, as determined by clinical impression from a CPP specialist. Clinical impression will be based on the presence of the following symptoms and physical findings:

    a. Symptoms: i. CPP increased with standing, walking, or lifting ii. CPP increased at the end of the day iii. CPP improved by laying down iv. Sexually provoked prolonged post-coital ache b. Physical findings: i. Adnexal tenderness on gentle bimanual exam ii. Tenderness at the ovarian point trans-abdominally iii. Tenderness of the uterus

  6. Participant can read, communicate clearly, and understand English or Spanish.
  7. Participant is willing and able to participate in an interview and complete questionnaires.
  8. Participant is willing and able to provide informed consent.

Exclusion Criteria:

  1. Pain symptoms should primarily be of pelvic and/or pelvic floor origin (inclusion criteria #3 above). Pain should not be exclusively low back, hips, symphysis, allodynia or hyperalgesia of the skin, or from varicose veins of the vulvar and/or lower extremities.
  2. Pain thought primarily to be due to endometriosis, pelvic floor myalgia, a musculoskeletal etiology, irritable bowel disease, or painful bladder syndrome/interstitial cystitis.
  3. Obvious endometriosis based on physical exam or laparoscopy findings.
  4. Patients previously treated with a technically successful surgery or vascular procedure for a venous disorder of the pelvis or renal vein.
  5. Participant has any clinically relevant medical condition (e.g., severe co morbid condition, severe mental illness, severe visual or auditory impairment, or cognitive impairment) that, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
55 participants (estimated)
Patient registry
No

Groups and cohorts

  • Chronic pelvic pain of venous origin

    Women who are thought to have chronic pelvic pain of venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being.

    Other: Qualitative interview

  • Chronic pelvic pain of non-venous origin

    Women who are thought to have chronic pelvic pain of a non-venous origin will be interviewed to determine the impacts of their pain on physical, social and emotional aspects of their health and well being. They will be asked of the concepts identified by the women with venous origin CPP apply to them and if the impacts of the pain are similar or differ.

    Other: Qualitative interview

Interventions

  • OtherQualitative interview

    Qualitative interviews will be performed on women with chronic pelvic pain of venous origin.

06

What researchers measure

Primary outcomes

  1. Phase 1 qualitative concept elicitation interview

    Phase 1 qualitative interview about VO-CPP (Chronic pelvic pain originating from venous contribution) signs, symptoms, and impacts, from which a novel VO-CPP questionnaire (PeVD HRQoL) will be drafted, and ultimately assessed for content validity in the Phase 2 interviews. This Phase 1 interview will be conducted with subjects with VO-CPP.

    Time frame: 1 month

Secondary outcomes

  1. Phase 2 Qualitative cognitive interview

    Phase 2 qualitative interview will include questions about item clarity, how the participants interpret the items, ease of completing the PeVD HRQoL questions, questionnaire comprehensiveness, and the appropriateness of the questionnaire format and response scales. This Phase 2 interview will be conducted with subjects with VO-CPP.

    Time frame: 1 month

  2. Phase 2 qualitative open-ended concept elicitation questions

    Phase 2 qualitative open-ended concept elicitation questions. This Phase 2 interview will be conducted with subjects with chronic pelvic pain originating from non-venous causes (NVO-CCP).

    Time frame: 1 month

  3. Phase 2 qualitative cognitive interview

    Phase 2 qualitative interview about the content validity of the novel questionnaire, PeVD HRQoL, with subjects with chronic pelvic pain originating from non-venous causes (NVO-CCP).

    Time frame: 1 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol, informed consent forms, de-identified data, analytic process and the clinical study report will be available for other researchers. The final patient reported outcome instrument will be made available for use by any investigator for clinical research by the study funder SIR Foundation

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anticipated January 2025

Access criteria: The study protocol, consents and data supporting the PROM instrument will be made available for research purposes to investigators by the study PI. The final patient reported outcome instrument will be made available for use by any investigator for clinical research by license by the study funder SIR Foundation

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Oct 16, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06083597
Collaborators
Society of Interventional Radiology Foundation, Evidera
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Jul 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 18, 2025

Study contacts

Neil M Khilnani, MD
principal investigator · Weill Medical College of Cornell University
Robin Pokrzywinski, PhD
study director · Evidera

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion